

CLINICAL TRIALS WATCH

ACCESSIBLE EASY READ INFORMATION ON:

TRAILRUNNER-ALZ 3 STUDY

TRAILRUNNER-ALZ 3 study

1. Study Information	
Name of the study	A study of remternetug (LY3372993) in early Alzheimer's disease
Study sponsor	Eli Lilly
Disease	Early Alzheimer's disease (preclinical Alzheimer's disease and Mild Cognitive Impairment due to Alzheimer's disease)
Phase	Phase III

2. Information about the drug that will be tested in the study	
Name of drug	Remternetug (LY3372993)
Administration	The drug will be administered via a subcutaneous injection (an injection under the skin).
Is the drug already on the market for another medical condition?	No
Will all participants receive the same drug?	<p>Participants will be selected by chance to receive one of the following options:</p> <ul style="list-style-type: none">• A subcutaneous injection of remternetug• A subcutaneous injection of placebo (also called a dummy treatment which is an inactive substance identical in appearance to the drug being tested with no active therapeutic effect). <p>Neither the participant nor their doctor will know if the person is receiving the investigational drug or the placebo.</p>

3. Information about participating in the trial	
What are the researchers trying to find out?	<ul style="list-style-type: none">• The study will evaluate the safety and efficacy of remternetug in participants who have early Alzheimer's disease. The primary objective will assess whether treatment with remternetug delays the time to clinically meaningful progression as compared to placebo.

<p>How long will the treatment last?</p>	<ul style="list-style-type: none"> • This study will last about 5 years, including a screening, a treatment period of 78 weeks and an observation period • In addition, eligible participants who receive placebo during the treatment period may choose to extend their study participation to receive remternetug in an extension period.
<p>What your involvement will entail?</p>	<ul style="list-style-type: none"> • During the study, participants will be asked to complete tests that will assess their memory, cognition, functional and daily activities (MMSE, FAQ, CDR-SB, MoCA, ADCS) • Complete some laboratory tests and neurological examination to evaluate the emergent adverse events (unfavourable signs, symptoms or diseases temporally associated with the use of the drug tested in the study) • Undergo brain scans (MRI). <p>Further information on the procedures, tests and number of visits can be obtained from the study team.</p>

<p>4. Who can participate in this study?</p>	
<p>Who can participate in the study?</p>	<p>To take part in the study, participants must:</p> <ul style="list-style-type: none"> • Be between 55 and 80 years old • Have amyloid pathology in the brain (blood test) • Have a study partner who is willing to participate in study procedures throughout the study duration • Have adequate literacy, vision and hearing for neuropsychological testing • Have a score ≥ 27 in the MMSE test and < 6 in the Functional Activities Questionnaire. This would suggest that the person has no or only mild problems with memory and function

	<ul style="list-style-type: none"> • If the person is taking a symptomatic treatment for Alzheimer's disease, the dosing regimen must have been stable for at least 1-month weeks prior to the study inclusion.
Who cannot participate in the study?	<p>Exclusion criteria include:</p> <ul style="list-style-type: none"> • Have dementia or significant other neurological disease that can affect cognition • Have a current serious medical condition or abnormality that could increase the risk to their safety or could interfere with the results of this study • Have a history of severe drug allergies or hypersensitivity reactions • A disease that may interfere with the safety or study assessments (e.g., pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, cardiovascular, or oncologic disease) • Have any contraindications for brain scans (MRI). <p>The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.</p>

5. Where and when will the study be conducted?	
European country involved in the trial (active)	<ul style="list-style-type: none"> • UK
European country involved in the trial (planned)	<ul style="list-style-type: none"> • Spain
Estimated start date of recruitment	January 2025

6. Information for your doctor			
Clinicaltrials.gov identifier	NCT06653153	EU CT Number	2024-515656-20-00
Study contact information	clinical_inquiry_hub@lilly.com		
Link to full text	https://clinicaltrials.gov/study/NCT06653153 https://euclinicaltrials.eu/ctis-public/view/2024-515656-20-00		
Study's website	https://lillyadresearch.com/trailrunner-alz-3/		

- ✓ The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov, CTIS websites) in April 2025.